Extracorporeal Blood Purification with CytoSorb® Hemoadsorption in Valve Surgery for Infective Endocarditis: A Case Series
American Journal of Case Reports · 2025
DOI: 10.12659/ajcr.948318 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Case Reports, 2025. Verfasst von Živojin S Jonjev und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Cardiovascular Surgery, Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia. Hauptthemen laut MEDLINE: Cardiopulmonary Bypass, Endocarditis, Bacterial. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND Infective endocarditis (IE) is a life-threatening condition characterized by endocardial infection, systemic inflammation, and potential multi-organ dysfunction. Despite advances in surgical techniques and antimicrobial therapy, outcomes remain suboptimal in high-risk patients. Hemoadsorption using the CytoSorb® device has emerged as a potential adjunctive therapy to mitigate systemic inflammation during cardiopulmonary bypass (CPB) surgery, but its clinical benefit in IE remains under evaluation. CASE REPORT We describe a series of 4 adult patients with confirmed bacterial IE involving the aortic or tricuspid valve, all requiring urgent cardiac surgery. Each patient exhibited clinical signs of sepsis, persistent fever, elevated inflammatory markers, and vegetation on echocardiography. Intraoperatively, CytoSorb hemoadsorption was integrated into the CPB circuit. In all cases, a significant reduction in inflammatory markers (C-reactive protein, procalcitonin), lactate, and vasopressor requirements was observed within 24 hours postoperatively. Mechanical ventilation duration was below institutional averages. No patients required re-operation, mechanical circulatory support, or postoperative hemoadsorption. All were discharged between postoperative days 7 and 17, and follow-up at 6 months revealed no complications or relapses. CONCLUSIONS This case series suggests that intraoperative hemoadsorption using CytoSorb may be a beneficial adjunct in the surgical management of severe IE, particularly in patients with high inflammatory burden. Improvements in hemodynamic stability, inflammatory response, and postoperative recovery were consistently observed. These findings support the need for randomized controlled trials to evaluate patient selection criteria and confirm therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Clinic of Cardiovascular Surgery, Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia.
- Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.
- Clinic for Cardiovascular Surgery, Institute for Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia.
ORCID-Profile: Živojin S Jonjev
Zitieren
APA
Jonjev, Ž. S., Božić, A., Bjeljac, I., Hrubik, J., & Kalinić, N. (2025). Extracorporeal Blood Purification with CytoSorb® Hemoadsorption in Valve Surgery for Infective Endocarditis: A Case Series. American Journal of Case Reports. https://doi.org/10.12659/ajcr.948318
Vancouver
Jonjev ŽS, Božić A, Bjeljac I, Hrubik J, Kalinić N. Extracorporeal Blood Purification with CytoSorb® Hemoadsorption in Valve Surgery for Infective Endocarditis: A Case Series. American Journal of Case Reports. 2025. doi:10.12659/ajcr.948318
BibTeX
@article{Jonjev2025,
author = {Jonjev, Živojin S and Božić, Anđela and Bjeljac, Ilija and Hrubik, Jan and Kalinić, Novica},
title = {Extracorporeal Blood Purification with CytoSorb® Hemoadsorption in Valve Surgery for Infective Endocarditis: A Case Series},
journal = {American Journal of Case Reports},
year = {2025},
doi = {10.12659/ajcr.948318}
}
EUVIMED